Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Mar 10, 2025
Open Peer Review Period: Mar 10, 2025 - May 5, 2025
Date Accepted: Apr 21, 2025
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Digital Therapeutics for Cognitive Impairment: A Narrative Review of Innovative Applications and Emerging Challenges
ABSTRACT
Recent advancements in cognitive neuroscience and digital technology have significantly accelerated the adoption of digital therapeutics for cognitive impairment. This review provides a comprehensive overview of the innovative applications of digital therapeutics in the assessment, intervention, management and monitoring of cognitive disorders, while highlighting key challenges that impede their widespread integration into clinical practice. Drawing on the definition of cognitive digital therapeutics and the multi-stakeholder collaboration required for its development and implementation, this study explores the role of digital technologies in cognitive health and explores challenges from multiple perspectives, including clinical practice, policy framework, user adoption, ethics and privacy, and data interoperability and security. Additionally, the study offers strategic recommendations to promote the sustainable development and scalable implementation of cognitive digital therapeutics, particularly as artificial intelligence (AI) technologies continue to advance, addressing both current applications and emerging challenges.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.